Ratings Surperformance

Trader
Investor
-
Global
-
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings CStone Pharmaceuticals: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: CStone Pharmaceuticals
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: CStone Pharmaceuticals
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

CStone Pharmaceuticals SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

CStone Pharmaceuticals SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

CStone Pharmaceuticals SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

CStone Pharmaceuticals SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

CStone Pharmaceuticals SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.06B -
BB
- -
77.35B
BBB
59.58B
A
58.14B -
BBB
- -
47.62B
A
45.34B
AA
31.92B
AA
25.29B
AA
20.88B
AAA
15.64B
AA
Average 38.28B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 2616 Stock
  4. CSPHF Stock
  5. Ratings CStone Pharmaceuticals
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!